p(MGI:Mapt, pmod(Ph, Thr, 205))

Entity

Name

Mapt

Namespace

mgi

Namespace Version

20181021

Namespace URL

https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns

Tau Modifications Sections of NESTOR

Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE). PubMed:22798221

Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored. Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes. PubMed:24113872

Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation. PubMed:22798221

Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation. PubMed:22798221

Western blot analyses of brain homogenates show that (-)-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes (Fig. 3). PubMed:25331948